BR0308663A - Uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas - Google Patents

Uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas

Info

Publication number
BR0308663A
BR0308663A BR0308663-1A BR0308663A BR0308663A BR 0308663 A BR0308663 A BR 0308663A BR 0308663 A BR0308663 A BR 0308663A BR 0308663 A BR0308663 A BR 0308663A
Authority
BR
Brazil
Prior art keywords
prevention
treatment
peripheral vascular
vascular diseases
inhibitors
Prior art date
Application number
BR0308663-1A
Other languages
English (en)
Other versions
BRPI0308663B1 (pt
BRPI0308663B8 (pt
Inventor
Yolande Chavatchko
Alain Tedgui
Ziad Mallat
Original Assignee
Applied Research Systems
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems, Inst Nat Sante Rech Med filed Critical Applied Research Systems
Publication of BR0308663A publication Critical patent/BR0308663A/pt
Publication of BRPI0308663B1 publication Critical patent/BRPI0308663B1/pt
Publication of BRPI0308663B8 publication Critical patent/BRPI0308663B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Vascular Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Dermatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

"USO DE INIBIDORES DE IL-18 PARA O TRATAMENTO E/OU PREVENçãO DE DOENçAS VASCULARES PERIFéRICAS". A presente invenção refere-se ao uso de um inibidor de IL-18 na preparação de um medicamento para o tratamento e/ou prevenção de doenças vasculares periféricas. A presente invenção refere-se ainda ao uso de um inibidor de IL-18 para prevenção de amputação de membros.
BRPI0308663A 2002-03-22 2003-03-13 uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas BRPI0308663B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP02100290.2 2002-03-22
EP02100290 2002-03-22
PCT/EP2003/050061 WO2003080104A2 (en) 2002-03-22 2003-03-13 Use of il-18 inhibitors for the treatment and/or prevention of peripheral vascular diseases

Publications (3)

Publication Number Publication Date
BR0308663A true BR0308663A (pt) 2005-01-25
BRPI0308663B1 BRPI0308663B1 (pt) 2019-07-16
BRPI0308663B8 BRPI0308663B8 (pt) 2021-05-25

Family

ID=28051827

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0308663A BRPI0308663B8 (pt) 2002-03-22 2003-03-13 uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas

Country Status (27)

Country Link
US (2) US9592267B2 (pt)
EP (1) EP1487541B1 (pt)
JP (1) JP4885424B2 (pt)
KR (1) KR20050004809A (pt)
CN (1) CN100540058C (pt)
AR (1) AR039103A1 (pt)
AT (1) ATE414556T1 (pt)
AU (1) AU2003219162B2 (pt)
BR (1) BRPI0308663B8 (pt)
CA (1) CA2478855C (pt)
CY (1) CY1108748T1 (pt)
DE (1) DE60324777D1 (pt)
DK (1) DK1487541T3 (pt)
EA (1) EA008495B1 (pt)
ES (1) ES2314191T3 (pt)
HR (1) HRP20040758B1 (pt)
IL (2) IL164211A0 (pt)
ME (1) ME00548B (pt)
MX (1) MXPA04009135A (pt)
NO (1) NO336226B1 (pt)
PL (1) PL207303B1 (pt)
PT (1) PT1487541E (pt)
RS (1) RS51755B (pt)
SI (1) SI1487541T1 (pt)
UA (1) UA80275C2 (pt)
WO (1) WO2003080104A2 (pt)
ZA (1) ZA200407022B (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7914814B2 (en) 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
TWI335336B (pt) * 2000-02-10 2011-01-01 Abbott Gmbh & Co Kg
SI1487541T1 (sl) 2002-03-22 2009-02-28 Serono Lab Uporaba inhibitorjev il-18 za zdravljenje in /alipreventivo bolezni perifernega oĺ˝ilja
US7968684B2 (en) * 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
IL159670A0 (en) * 2003-12-31 2004-06-01 Yeda Res & Dev Use of il-18 binding protein in inflammations
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
WO2005102307A2 (en) * 2004-04-19 2005-11-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
EP2267024B1 (en) 2005-06-03 2012-05-09 Ares Trading S.A. Production of recombinant Il-18 binding protein
PT1891088E (pt) 2005-06-10 2011-12-19 Ares Trading Sa Processo para a purificação da proteína de ligação il-18
US8753690B2 (en) 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
EP2620139B1 (en) 2008-02-27 2016-07-20 Biomet Biologics, LLC Interleukin-1 receptor antagonist rich solutions
WO2010151241A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing naproxen
KR101643797B1 (ko) 2009-06-24 2016-07-28 스트러티직 사이언스 앤드 테크놀로지스, 엘엘씨 이부프로펜을 함유하는 국소 조성물
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US12138268B2 (en) 2009-06-24 2024-11-12 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
CA2772084C (en) 2009-08-27 2016-10-18 Biomet Biologics, Llc Implantable device for production of interleukin-1 receptor antagonist
EP2483406A2 (en) 2009-09-30 2012-08-08 President and Fellows of Harvard College Methods for modulation of autophagy through the modulation of autophagy-inhibiting gene products
JP5813114B2 (ja) 2010-08-25 2015-11-17 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｉｌ−１８ｒ１に対する抗体およびその使用
JP2014501283A (ja) 2010-12-29 2014-01-20 ストラテジック サイエンス アンド テクノロジーズ， エルエルシー アレルギーおよび他の適応症の処置のためのシステムおよび方法
EP4491225A3 (en) 2010-12-29 2025-03-26 Strategic Science & Technologies, LLC Treatment of erectile dysfunction and other indications
US9376489B2 (en) 2012-09-07 2016-06-28 Novartis Ag IL-18 binding molecules
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
US9895418B2 (en) * 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
EP3074507B1 (en) 2013-11-26 2022-01-05 Biomet Biologics, LLC Methods of mediating macrophage phenotypes
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
US10882905B2 (en) * 2015-03-05 2021-01-05 Ab2 Bio Sa IL-18 binding protein (IL-18BP) and antibodies in inflammatory diseases
US9763800B2 (en) 2015-03-18 2017-09-19 Biomet C. V. Implant configured for hammertoe and small bone fixation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5877197A (en) * 1996-12-16 1999-03-02 Karanewsky; Donald S. C-terminal modified (N-substituted)-2-indolyl dipeptides as inhibitors of the ICE/ced-3 family of cysteine proteases
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2276216A1 (en) 1998-06-24 1999-12-24 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo An artificial peptide capable of neutralizing the biological activity of interleukin-18
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
DE60041432D1 (de) * 1999-11-16 2009-03-12 Hayashibara Biochem Lab Antikörper spezifisch für den Interleukin-18 Vorläufer
EE05056B1 (et) * 2000-05-05 2008-08-15 Applied Research Systems Ars Holding N.V. IL-18 inhibiitorite kasutamine ravimi valmistamiseks, mis on ette n„htud ateroskleroosi ravimiseks ja/v?i ennetamiseks
PE20011350A1 (es) * 2000-05-19 2002-01-15 Vertex Pharma PROFARMACO DE UN INHIBIDOR DE ENZIMA CONVERTIDORA DE INTERLEUCINA-1ß (ICE)
AU2002224417A1 (en) * 2000-10-18 2002-04-29 Immunex Corporation Methods for treating il-18 mediated disorders
SI1487541T1 (sl) 2002-03-22 2009-02-28 Serono Lab Uporaba inhibitorjev il-18 za zdravljenje in /alipreventivo bolezni perifernega oĺ˝ilja

Also Published As

Publication number Publication date
PT1487541E (pt) 2008-12-10
US9566313B2 (en) 2017-02-14
EA200401240A1 (ru) 2005-02-24
WO2003080104A3 (en) 2004-03-04
BRPI0308663B1 (pt) 2019-07-16
CN100540058C (zh) 2009-09-16
ME00548B (me) 2011-10-10
PL372398A1 (en) 2005-07-25
HRP20040758B1 (hr) 2012-10-31
RS51755B (sr) 2011-12-31
CA2478855A1 (en) 2003-10-02
ES2314191T3 (es) 2009-03-16
WO2003080104A2 (en) 2003-10-02
ZA200407022B (en) 2006-06-28
CN1655845A (zh) 2005-08-17
HK1075422A1 (zh) 2005-12-16
NO20044459L (no) 2004-10-20
HRP20040758A2 (en) 2005-02-28
US20060233799A1 (en) 2006-10-19
ATE414556T1 (de) 2008-12-15
IL164211A0 (en) 2005-12-18
US20100291028A1 (en) 2010-11-18
PL207303B1 (pl) 2010-11-30
EP1487541A2 (en) 2004-12-22
DK1487541T3 (da) 2009-01-19
US9592267B2 (en) 2017-03-14
MXPA04009135A (es) 2004-12-07
RS81504A (sr) 2006-12-15
JP2005520852A (ja) 2005-07-14
CY1108748T1 (el) 2014-04-09
NO336226B1 (no) 2015-06-22
IL164211A (en) 2011-07-31
EA008495B1 (ru) 2007-06-29
AR039103A1 (es) 2005-02-09
UA80275C2 (en) 2007-09-10
DE60324777D1 (de) 2009-01-02
AU2003219162B2 (en) 2008-01-03
BRPI0308663B8 (pt) 2021-05-25
JP4885424B2 (ja) 2012-02-29
CA2478855C (en) 2013-12-17
SI1487541T1 (sl) 2009-02-28
KR20050004809A (ko) 2005-01-12
EP1487541B1 (en) 2008-11-19
AU2003219162A1 (en) 2003-10-08

Similar Documents

Publication Publication Date Title
BR0308663A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção de doenças vasculares periféricas
BRPI0410503A (pt) uso da ivermectina para a fabricação de uma composição farmacêutica tópica, composição tópica e uso da composição
BR0212907A (pt) Métodos para tratamento ou prevenção de inflamação vascular usando inibidor(es) da absorção de esteróis
CY1114448T1 (el) Φαρμακευτικες συνθεσεις και χρηση αυτων στην αγωγη της γυναικειας σεξουαλικης δυσλειτουργιας
BRPI0207961B8 (pt) uso de análogos de epotilona e capecitabina para fabricar medicamento para tratar tumores cancerosos sólidos e kit compreendendo os referidos compostos.
ECSP045520A (es) Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos
BR0207883A (pt) Composições de medicamentos à base de anticolenérgicos e inibidores de pde-iv
BR0110506A (pt) Uso de inibidores de il-18 para o tratamento e/ou prevenção da aterosclerose
BRPI0415753A (pt) método para tratamento e prevenção da inflamação respiratória com um inibidor de ciclooxigenase-2 em associação com um inibidor de fosfodiesterase 4 e composições que os contêm
BR0010531A (pt) Composições e usos de et743 para tratamento de câncer
WO2004100893A3 (en) Methods for treatment of inflammatory diseases using ct-3 or analogs thereof
AU7862401A (en) Pharmaceutical compostion comprising trkaig2 for use in the prevention and/or treatment of cancer
BR0206819A (pt) Uso de inibidores de il-18 para o tratamento e/ou para a prevenção de doença cardìaca
BR0108980A (pt) Aplicação e formulação farmacêuticas compreendendo inibidor de reabsorção de norepinefrina
PT1220676E (pt) Prevencao do cancro colorrectal
WO2001070233A3 (en) Apoptosis inhibiting composition comprising a 15-keto-prostaglandin or derivative thereof
BR0306778A (pt) Derivados de carboxamidina e seu uso no tratamento de doenças vasculares
WO2003007876A3 (en) N-fatty acid-amino acid conjugates and therapeutic uses
BR0210910A (pt) Derivados de imidazotriazinonas e sua aplicação contra processos inflamatórios e/ou doenças imunes
BR0213410A (pt) Usos farmacêuticos de bisfosfonatos
BR0211827A (pt) Uso de inibidores de il-18 em distúrbios de hipersensibilidade
BR0315374A (pt) Compostos orgânicos
BRPI0408322A (pt) uso de um fibrato e orlistat para o tratamento da obesidade
BR0104005A (pt) Composição farmacêutica para a prevenção ou para o tratamento de uma doença associada com um excesso de produção de il-2
WO2003011309A3 (de) Verwendung einer calciumhaltigen pharmazeutischen zusammensetzung zur behandlung von hypercholesterinämie

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M

Free format text: TRANSFERIDO DE: APPLIED RESEARCH SYSTEMS ARS HOLDING N.V.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25D Requested change of name of applicant approved

Owner name: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE M

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PEDIDO DE ACORDO COM O(S) ARTIGO(S) 8O C/C 13 E 25 DA LPI.

B12B Appeal against refusal [chapter 12.2 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 16/07/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 13/03/2003 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF

B21A Patent or certificate of addition expired [chapter 21.1 patent gazette]

Free format text: PATENTE EXTINTA EM 13/03/2023